Capable of providing daily triaging of everyone who may or may not demonstrate levels of infection, UK-based Integumen has designed, built and tested a prototype that can analyse the breath and detect the spike protein of SARS-CoV-2 in real-time for those with a high viral load. The prototype has undergone internal testing and will now transition to a containment level 3 laboratory, to undergo tests directly on the virus followed by a joint trial of up to 5,000 participants in parallel with third parties using reverse transcription polymerase chain reaction (“rtPCR”) and antigen tests. Results are anticipated before the end of the year when it is expected to be designated a Class 1 medical device.
